Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cloxacillin + amikacin is a combination of two antibiotics used primarily for the treatment of severe bacterial infections, including neonatal and pediatric sepsis and right-sided infective endocarditis. Cloxacillin is a semisynthetic beta-lactam antibiotic in the penicillin class, effective against staphylococci (including beta-lactamase-producing strains) by inhibiting bacterial cell wall synthesis. Amikacin is an aminoglycoside antibiotic that binds to the 30S ribosomal subunit, inhibiting protein synthesis and leading to bacterial cell death; it is particularly active against Gram-negative bacteria and some Gram-positive organisms. This combination is recommended as a second-choice regimen for suspected or confirmed infections due to Staphylococcus aureus or gentamicin-resistant Gram-negative bacilli, especially in neonates and children[1][2][4][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cloxacillin + amikacin.